冠心病介入治疗相关造影剂肾病防治的研究进展

随着冠状动脉介入技术在疾病诊断、评估、治疗中的应用日益广泛，造影剂肾病发病率不断升高。多数情况下造影剂肾病是可逆的，但任其发展会增加肾脏及心血管不良事件的发生率。因此如何有效预防和减少造影剂急性肾损伤的发生、减少高危患者不良事件发生成为现阶段心血管介入诊疗并发症防治研究的热点。结合2018年欧洲心脏协会血运重建指南中造影剂肾病的防治推荐，本文对当前造影剂肾病的危险因素、病理生理机制、早期损伤标志物、防治策略等方面进行梳理与总结。

Advances in prevention of contrast-induced nephropathy after coronary angiography or intervention

With the application of coronary angiography or intervention in the diagnosis, evaluation and treatment of coronary heart diseases, the incidence of contrast induced nephropathy is increasing. The contrast induced nephropathy are reversible in most patients, but it will increase the incidence of renal and cardiovascular adverse events. Therefore, how to effectively prevent and reduce the incidence of contrast induced acute kidney injury and reduce the incidence of adverse events in high-risk patients has become the focus of the current researches. According to the recommendations for the prevention and treatment of contrast nephropathy in the 2018 guidelines of the European Heart Association, this paper reviewed and summarized the current research progress in the prevention and treatment of the contrast induced nephropathy.